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ABSTRACT
Colorectal cancer (CRC) remains one of the leading causes of cancer related 
deaths in the United States. Currently, there are limited therapeutic options for 
patients suffering from CRC, none of which focus on the cell signaling mechanisms 
controlled by the popular kinase family, cyclin dependent kinases (CDKs). Here we 
evaluate a Pfizer developed compound, CP668863, that inhibits cyclin-dependent 
kinase 5 (CDK5) in neurodegenerative disorders. CDK5 has been implicated in a 
number of cancers, most recently as an oncogene in colorectal cancers. Our lab 
synthesized and characterized CP668863 – now called 20-223. In our established 
colorectal cancer xenograft model, 20-223 reduced tumor growth and tumor weight 
indicating its value as a potential anti-CRC agent. We subjected 20-223 to a series 
of cell-free and cell-based studies to understand the mechanism of its anti-tumor 
effects. In our hands, in vitro 20-223 is most potent against CDK2 and CDK5. The 
clinically used CDK inhibitor AT7519 and 20-223 share the aminopyrazole core and we 
used it to benchmark the 20-223 potency. In CDK5 and CDK2 kinase assays, 20-223 
was ~3.5-fold and ~65.3-fold more potent than known clinically used CDK inhibitor, 
AT7519, respectively. Cell-based studies examining phosphorylation of downstream 
substrates revealed 20-223 inhibits the kinase activity of CDK5 and CDK2 in multiple 
CRC cell lines. Consistent with CDK5 inhibition, 20-223 inhibited migration of CRC 
cells in a wound-healing assay. Profiling a panel of CRC cell lines for growth inhibitory 
effects showed that 20-223 has nanomolar potency across multiple CRC cell lines and 
was on an average >2-fold more potent than AT7519. Cell cycle analyses in CRC cells 
revealed that 20-223 phenocopied the effects associated with AT7519. Collectively, 
these findings suggest that 20-223 exerts anti-tumor effects against CRC by targeting 
CDK 2/5 and inducing cell cycle arrest. Our studies also indicate that 20-223 is a 
suitable lead compound for colorectal cancer therapy.
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INTRODUCTION
Colorectal cancer (CRC) continues to be a major 
health concern in the United States where it is currently 
the fourth most commonly diagnosed malignancy and the 
second leading cause of cancer related deaths [1]. Despite 
numerous attempts at developing promising therapies for 
CRC, few have successfully improved patient outcome.
Cyclin-dependent kinases (CDKs) have been 
extensively studied and characterized for their roles in 
cancer. There are 20 members of the CDK family, all 
of which have been linked to cancer. CDKs are often 
categorized into two major groups, those that contribute 
to tumorigenesis through cell cycle control and those 
that regulate transcription [2–4]. One peculiar member of 
the CDK family that does not regulate transcription and 
only recently has been shown to contribute to cell cycle 
progression, is CDK5. Uniquely, CDK5 is not activated in 
typical CDK fashion i.e., through binding of cyclins, but 
instead is activated by regulatory proteins p35 and p39 
[5]. CDK5 is best known for its role in the central nervous 
system where it regulates development, axon elongation, 
synaptogenesis and neuronal migration. Recently, reports 
have identified CDK5 as a key player in non-neuronal 
functions including apoptosis, senescence, angiogenesis, 
insulin secretion, wound healing, and adhesion/migration 
[6]. These functions associated with CDK5 are believed 
to contribute to its role in tumorigenesis. CDK5 has been 
previously implicated in a number of cancers, including 
those of the pancreas [7, 8], thyroid [9, 10], prostate [11, 
12], breast [13], lung [14], liver [15], and most recently as 
a tumor promoter in CRC [16].
CDKs have received a lot of attention as potential 
targets for cancer therapy. The traditional approach to 
targeting CDKs, which still remains popular, is through 
the use of ATP-competitive inhibitors that bind within 
the catalytic sites of CDKs and outcompete the binding 
of ATP. The earliest CDK inhibitors were pan-CDK 
inhibitors that often targeted most, if not all the members 
of the family. While they showed promise in targeting 
CDKs, they often required high doses which resulted in 
off-target effects and significant toxicity in preclinical 
animal trials [17]. To address these issues, substantial 
efforts have been made to improve upon the potency of 
CDK inhibitors. While CDK inhibitors are currently being 
used to treat a variety of malignancies, few are currently 
being tested in CRC [18].
ATP competitive inhibitors typically form hydrogen 
bonds with the residues in the hinge region of the kinase. 
Aminopyrazole is a privileged scaffold that forms a 
network of hydrogen bonds between 3 nitrogen atoms of 
the scaffold and the hinge region of the kinase [19, 20]. 
AT7519, a well-characterized pan-CDK inhibitor built on 
a 4-aminopyrazole core has shown promise in pre-clinical 
and clinical studies [21–23].
Herein, we describe our findings with a 
3-aminopyrazole analog previously reported by Pfizer 
(CP668863 a.k.a 20-223), that was developed to treat 
neurodegenerative disorders [23]. Preliminary xenograft 
studies showed 20-223 reduced tumor growth and tumor 
weight in vivo indicating that 20-223 is a suitable lead 
compound for CRC therapy. We subjected 20-223 and 
AT7519 to a series of cell-free and cell-based assays to 
understand the mechanistic basis of the observed 20-223 
anti-tumor effects. Docking studies suggested both 20-
223 and AT7519 are ATP competitive inhibitors. The two 
aminopyrazole analogs were compared head-to-head in 
cell free kinase assays which demonstrated 20-223 was 
more potent than AT7519. Contrary to a previous report, 
we found 20-223 was equipotent against CDK2 and 
CDK5 compared to other members of the CDK family. 
Examination of downstream substrate phosphorylation 
showed 20-223 inhibited the kinase activity of CDK2 and 
CDK5. Migration studies utilizing a wound-healing assay 
showed that 20-223 decreased CRC cell migration. 20-
223 was a nanomolar inhibitor of cell growth in a panel of 
CRC cell lines and was more potent than AT7519. Finally, 
20-223 phenocopied cell cycle effects associated with 
AT7519. Together, our studies suggest 20-223 is a CDK 
2/5 inhibitor, an effective anti-CRC agent and suitable lead 
for pre-clinical development.
RESULTS
TCGA analyses reveals CDK5 is upregulated 
in primary colorectal tumors as a result of 
increased copy number
With increasing evidence suggesting a role for 
CDK5 in a variety of malignancies, we turned to The 
Cancer Genome Atlas (TCGA – http://cancergenome.nih.
gov/) database to gain insight into CDK5 expression in 
patient populations. We found the colorectal cancer cohort 
in TCGA online database consisted of 50 samples of 
normal mucosa and 347 primary colorectal tumor samples. 
The mRNA profiles of these samples were examined for 
CDK5 expression. As seen in Supplementary Figure 1A, 
CDK5 mRNA levels were significantly higher in primary 
tumor compared to normal colon. Additional analyses 
that compared normal tissue with corresponding primary 
tumor revealed that of the 31 patients examined, all but 
two showed a significant increase in CDK5 levels in 
primary tumors when compared to normal colon tissue 
(Supplementary Figure 1B). Next we examined the CDK5 
copy number to determine whether increased CDK5 
levels correspond to increased copy number. Of the 616 
sequenced CRC samples, few exhibited homozygous 
deletion or heterozygous loss of CDK5 (0.3% and 1.9% 
respectively). Interestingly, 46.0% of individuals were 
diploid for CDK5 while 51.9% of individuals had a copy 
number gain for CDK5 (Supplementary Figure 1C). 
Additionally, we found that across all four groups, there 
is a significant linear trend. As copy number of CDK5 
increases there is a corresponding increase in mRNA 
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expression (Supplementary Figure 1D) thus suggesting 
that copy number is a contributing factor to increased 
mRNA expression that we observed in CRC. Next, we 
investigated whether CDK5 mutation could possibly be 
contributing to its activity in CRC so we examined the 
mutational frequency of CDK5 in all TCGA cancers. We 
found that CDK5 is rarely mutated across cancers and 
more importantly is not mutated in CRC (Supplementary 
Figure 1E). Collectively, this data suggests that CDK5 
activity is a result of increased expression that results 
from an increase in copy number. Furthermore, it is the 
increase in CDK5 expression, not a mutation, which is 
likely responsible for its contributions to CRC. These 
data are consistent with a recent report implicating 
CDK5 as a tumor promoter in CRC and thus warrants 
the investigation into inhibition of CDK5 as a potential 
therapeutic option for CRC [16].
20-223 shows anti-tumor activity in human CRC 
xenograft tumors
CP668863, a substituted 3-aminopyrazole analog, 
was first reported by Pfizer as an ATP-competitive 
CDK5 inhibitor that was explored for the treatment 
of neurodegenerative disorders [24]. With increasing 
evidence that CDK5 activity contributes to CRC 
tumorigenesis, we synthesized CP668863 (a.k.a 20-223) 
to screen for its efficacy against CRC. We utilized our well 
established CRC xenograft model [25] to determine the 
effects of 20-223 in vivo. GEO cells were chosen because 
they form primary tumors 100% of the time and frequently 
exhibit metastatic spread (approximately 53%) in animal 
models [26]. As our xenograft model uses GEO cells, 
we performed an initial growth inhibition study to show 
efficacy of 20-223 in this cell line. We found 20-223 to 
have an IC
50
 value of 79nM in GEO cells (Figure 1A). We 
used a GEO cell line in which GFP is stably expressed, for 
our xenograft model. GEO-GFP cells were subcutaneously 
injected into the flank of athymic nude mice and allowed 
tumors to grow to ~100 mm3. Animals with tumors 
were then randomly divided into two treatment groups 
(I) DMSO or (II) 8mg/kg 20-223. In preliminary PK 
studies, mice were dosed with 8mg/kg of 20-223. The 
plasma concentration was greater than 79nM for 24 hours 
as determined by LC-MS (Supplementary Figure 2A). 
Subcutaneous injections were given in the shoulder area 
of each mouse daily for the first week and every other 
day for the following two weeks (Figure 1B). The mice 
were weighed and tumor volumes were measured every 
other day. At the end of the three-week treatment period 
the mice were euthanized and the tumors excised, weighed 
and imaged (Supplementary Figure 2B).
Average changes in tumor volume for both 
treatment groups are summarized in Figure 1C. At the 
end of the first week of treatment, average tumor volume 
in the DMSO-treated group was approximately 2-fold 
greater than average tumor volume in the 20-223-treated 
group (~429mm3 vs. ~197mm3). The tumor volumes 
of DMSO-treated animals continued to grow rapidly, 
while the tumor progression in 20-223-treated animals 
was slower (Figure 1C). At the conclusion of the study, 
tumors from the DMSO treated mice were significantly 
larger (~3-fold: 1138 mm3 vs. 386 mm3) than the tumors 
from the 20-223-treated mice. We also found a decrease in 
GFP fluorescence in 20-223-treated tumors compared to 
DMSO-treated tumors, which is consistent with the tumor 
volume trends (Figure 1D). The average tumor weights 
from DMSO-treated mice were also ~2-fold greater than 
tumors from 20-223-treated mice (0.7g vs. 0.3g) (Figure 
1E). Of note, 20-223 treated animals did not exhibit any 
overt signs of toxicity, as there was no change in animal 
weight or behavior.
To confirm inhibition of CDK5 in vivo, we 
performed western blot analyses on the tumor lysates 
with tumors from three representative animals from each 
treatment group. 20-223-treated tumors showed a decrease 
in the pFAK levels, a phosphorylation site specific to 
CDK5 [27], (Supplementary Figures 2C) suggesting 
inhibition of CDK5 in vivo. In summary, these studies 
suggest that 20-223 treatment results in anti-tumor activity 
in a CRC xenograft model.
20-223 is an ATP-competitive inhibitor
Our in vivo data suggests 20-223 may be a 
promising therapeutic agent for CRC, therefore we began 
to evaluate and characterize it in cell-free and cell-based 
studies. We started with docking studies that compared 20-
223 to another known CDK inhibitor, AT7519, which is 
currently in clinical trials and shares the aminopyrazole 
core structure with 20-223 [21, 23].
X-ray crystallographic studies of reported 
aminopyrazole analogs and CDKs showed that they 
occupy the ATP binding site in the CDKs [18, 19]. Since 
there is no co-crystal structure of 20-223, we docked 
20-223 into CDK5 using Autodock Vina to explore its 
binding mode. Our docking studies revealed that 20-
223 indeed occupied the ATP binding site of CDK5 and 
the three nitrogen atoms of the 3-aminopyrazole core 
are involved in a donor-acceptor-donor hydrogen bond 
triad with Glu81 and Cys83 of the hinge region. The 
cyclobutyl ring occupied a narrow hydrophobic pocket 
formed by Phe80, Leu55 and Val64 and the naphthalene 
ring of 20-223 is directed towards the solvent-accessible 
region of the kinase (Figure 2A). Since CDK2 and CDK5 
share sequence homology of ~60% (5), we overlaid 
the co-crystal structure of an aminopyrazole analog 
PNU-181227-CDK2 with our docked 20-223-CDK5 
and observed similar binding mode (Figure 2B). X-ray 
crystallographic studies demonstrated AT7519 to be an 
ATP-competitive CDK inhibitor [21]. Overlay of AT7519 
complexed with CDK2 and docked 20-223-CDK5 showed 
Oncotarget5219www.impactjournals.com/oncotarget
similar mode of binding with similar hydrogen bonding 
interactions anchoring the molecules to the hinge region 
(Figure 2C). The chemical structures of all three of these 
compounds are compared in Figure 2D.
Cell free kinase assays reveal 20-223 is a CDK 
2/5 inhibitor
In order to determine the selectivity profile of 
20-223 for various CDKs we conducted a single dose 
Figure 1: 20-223 exhibits anti-tumor activity in a colorectal cancer xenograft model. (A) Growth Inhibition of GEO cells 
after 72 hour treatment with 20-223. (B) Schematic representation of CRC xenograft model using GEO-GFP cells. (C) Average tumor 
volume comparison of DMSO and 20-223 treated tumors throughout the study. (D) Average GFP Flurorescence in DMSO and 20-223 
treated tumors. (E) Average tumor weight of DMSO and 20-223 treated tumors.
Oncotarget5220www.impactjournals.com/oncotarget
kinase screen with a panel of CDKs. Members of the 
CDK family bound to their respective activators were 
LQFXEDWHG ZLWK ȝ0 RI  DQG ȝ0$73 7KH
percentage remaining enzymatic activity was determined 
for each of the examined CDKs after inhibition by 20-223 
(Figure 2E). Incubation with 20-223 markedly inhibited 
the enzymatic activity CDK2 and CDK5 with only 0.26% 
and 0.39% enzymatic activity remaining. 20-223 was 
less effective against the enzymatic activity of CDK1, 
CDK4, CDK6, CDK7, and CDK9. These results show 
that 20-223 is most effective against CDK2 and CDK5 
in a cell-free system. To determine IC
50
 values of 20-223 
against CDK2/5 we performed a dose-response study. 
CDK2/CyclinE and CDK5/p35 were incubated with 20-
223 at various concentrations and IC
50
 values of 6.0nM 
for CDK2 and 8.8nM for CDK5 were derived from curve 
fitting the data (Figure 2F). Similar studies were also 
carried out with AT7519 and IC
50
 values of 392nM for 
CDK2 and 32.8nM for CDK5 were obtained. Results from 
the dose-response study show that 20-223 is equipotent 
against CDK2 and CDK5 in a cell-free system and is more 
potent than comparable CDK inhibitor, AT7519.
CDK2 and CDK5 expression and 
phosphorylation activity in a panel of human 
CRC cell lines
Having determined that 20-223 targets CDK2 and 
CDK5, we next examined the basal levels of these kinases 
in a cohort of colorectal cancer cell lines which includes 
seven CRC cell lines and one normal human colon 
epithelial cell line (HCEC). All the cell lines expressed 
CDK2 and CDK5, albeit at different levels. HCEC cells 
also expressed CDK2 and CDK5 but at much lower 
levels than many of the CRC cell lines (Figure 3A). This 
observation is consistent with the TCGA data.
As a measure of CDK2 and CDK5 activity we 
examined basal phosphorylation levels of substrates 
specific to CDK2 and CDK5. Phosphorylation levels 
of RB (S807/811) were used as a read-out for CDK2 
kinase activity. While CDK4 has also been shown to 
phosphorylate RB at S807/811 [28, 29], our kinase profile 
screen showed 20-223 targets CDK2/5 more effectively 
than CDK4/6. Phosphorylation levels of FAK (S732) were 
used as a read out for CDK5 kinase activity [27] [28]. We 
observed differential phosphorylation of RB (S807/811) 
and FAK (S732) indicating both CDK2 and CDK5 are 
active in each of the cell lines (Figure 3A).
20-223 disrupts CDK2 and CDK5 kinase activity 
in cell-based studies
Since 20-223 was shown to most potently inhibit 
CDK2 and CDK5 in a cell-free system, we next explored 
the ability of 20-223 to target CDK2 and CDK5 in a 
cellular setting. To characterize the effects of 20-223 on 
substrate phosphorylation, three CRC cell lines were 
chosen: GEO, HCT116 and HT29. CRC cells were 
LQFXEDWHGZLWK'062RUYDULRXVFRQFHQWUDWLRQVȝ0
– 2-fold dilutions, 7 doses) of 20-223 for 6 hours prior 
to western blot analyses. In the dose response study, 20-
223 did not affect the total levels of CDK2 or CDK5 
(Figure 3B), nor did it affect the levels of total FAK or 
total RB (Supplementary Figure 3). As expected, 20-223 
induced a dose-dependent decrease in pRB (S807/811) 
and pFAK (S732) levels in each of the three CRC cell 
lines (Figure 3B). Quantification of phosphorylated RB 
and FAK levels was performed to reveal the effect of the 
inhibitor on CDK2 and CDK5 kinase activity, respectively. 
As the concentration of 20-223 increased, there was a 
corresponding increase in % kinase inhibition for CDK2 
and CDK5 (Figure 3C). This pattern was consistent 
for each of the three cell lines. Quantification was also 
used to assess the fold selectivity of 20-223 in each of 
the three cell lines. Figure 3D summarizes the cell-based 
IC
50
 values for each cell line. 20-223 was ~10 fold more 
VHOHFWLYHIRU&'.RYHU&'.LQ*(2FHOOVȝ0
YVȝ0DQGaIROGPRUHVHOHFWLYHIRU&'.RYHU
&'.LQ+&7FHOOVȝ0YVȝ0+RZHYHU
in HT29 cells, 20-223 was equally potent against CDK5 
DQG&'.ȝ0YVȝ0:KLOHWKHJHQHUDWHG,&
50
values are based on a qualitative observation, these results 
demonstrated that 20-223 effectively blocks the kinase 
activity of CDK2 and CDK5 in multiple CRC cell lines.
20-223 reduces migration of CRC cells
Since 20-223 effectively inhibits CDK2 and CDK5, 
both of which have previously been shown to regulate cell 
motility [27, 30], we next examined its ability to disrupt 
CRC cell migration. Wound-healing scratch assays are 
routinely used to assess the effect of small molecule 
inhibitors on the ability of cells to migrate [31]. EGF-
stimulated wound healing has previously been shown to 
enhance migration of cells; therefore, we used this ligand 
to stimulate CRC cells for migration [32]. We checked 
protein levels of CDK2/5 and their substrates after EGF 
stimulation (100ng/mL) to ensure that treatment with 
EGF would not affect their basal levels or activity. Upon 
treatment with EGF, no changes in the levels of CDK2/5 
or pRB/pFAK were observed, indicating that EGF is 
not affecting the expression or activity of these kinases 
(Supplementary Figure 4A). HCT116 cells were used 
to model cell migration because they have been used 
previously in wound-healing scratch assays [35]. To 
assess the ability of 20-223 to inhibit migration, HCT116 
cells were stimulated with EGF and treated with DMSO 
RUȝ0RI/LYHFHOO LPDJLQJZDVXWLOL]HG WR
monitor cell motility through the 24 hour incubation period 
at 15 min intervals (Supplementary Figure 4B & 4C). Still 
images and zoomed in regions of the images emphasize 
the ability of 20-223 to inhibit cell migration (Figure 4A). 
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Figure 2: Structural and cell free analyses of 20-223 and AT7519. (A) Docking of 20-223 into CDK5 using AutoDock Vina 
software. (B) Overlay of 20-223 and PNU181227 in the hinge region of CDK5. (C) Overlay of 20-223 and AT7519 in the ATP binding 
pocket. (D) Chemical structures of 20-223, PNU-181227, and AT7519. (E) % of remaining enzymatic activity of a panel of CDKs after 
LQFXEDWLRQZLWKȝ0DQGȝ0$73(F) IC
50
 values (nM) of CDK2 and CDK5 after incubation with 20-223 or AT7519 in cell 
free dose-escalation study.
Oncotarget5222www.impactjournals.com/oncotarget
Figure 3: 20-223 inhibits the kinase activity of CDK5 and CDK2 in vitro. (A) Baseline expression of CDK2 and pRB (S807/811) 
(left), CDK5 and pFAK (S732) (right), in untreated CRC cells. (B) Representative western blots of target substrate pRB and pFAK 
phosphorylation levels in GEO (left), HCT116 (middle) and HT29 (right) cell lines after 6 hour incubation with 20-223. (C) Representative 
quantification of % inhibition of CDK2 and CDK5 kinase activity (based on substrate phosphorylation levels) in GEO cells found in Figure 
3B. (D) Cell-based IC
50
 values generated from phosphorylation levels in Figure3B of CDK2 and CDK5 in three CRC cell lines.
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HCT116 cells treated with DMSO had greater ability 
to migrate into the open wound areas compared to cells 
treated with 20-223. While cells treated with DMSO were 
able to close approximately 40% of the wound area, cells 
treated with 20-223 only closed approximately 10% of the 
wound (Figure 4B). To confirm that the reduced migration 
was a result of CDK2/5 inhibition, corresponding western 
blots were performed under the same conditions as the 
migration experiment and pFAK and pRB levels were 
GHWHUPLQHGDIWHUWUHDWPHQWZLWK(*)DQGȝ0RI
223. Although treatment with 20-223 effectively reduced 
the phosphorylation levels of both FAK (S732) and RB 
(S807/811) (Figure 4C), the effects were more pronounced 
on the FAK phosphorylation over RB phosphorylation. 
Collectively, these results suggest that inhibition of 
CDK2/5 by 20-223 disrupts CRC cell migration.
20-223 reduces cell growth in a panel of human 
CRC cell lines
Since 20-223 effectively targets CDK2 and CDK5, 
we next examined its effect on cell growth. We subjected 
a panel of CRC cell lines to treatment with three CDK 
inhibitors (20-223, AT7519 or Roscovitine). Roscovitine, 
which contains a purine core, was one of the first CDK 
inhibitors to enter clinical trials. CRC cells were treated 
with 20-223, AT7519 and Roscovitine at four-fold 
GLOXWLRQVVWDUWLQJDWȝ0DQG$7RUȝ0
(Roscovitine). Among the three inhibitors, 20-223 had 
lower IC
50
 values when compared to the clinically used 
CDK inhibitors, AT7519 and Roscovitine (Figure 5A). 
Among the CRC cell lines, SW620, GEO and FET cells 
were the most sensitive to 20-223, whereas HCT116 
and HT29 were more responsive to AT7519 treatment 
as evident by lower IC
50
 values. It is important to note 
that a ~10-fold higher dose of Roscovitine was required 
to observe similar growth inhibitory effects. Average IC
50
 
values were calculated across cell lines to determine the 
overall efficacy for each compound (Figure 5B). 20-223 
had an overall average IC
50
 value of 362nM across seven 
cell lines, while AT7519 and Roscovitine had overall 
average IC
50
 values of 799nM and 11481nM respectively, 
thus suggesting 20-223 is a more potent inhibitor of 
cell growth compared to the clinical compounds. CRC 
mutational profiles [33–39] (Figure 5C) were examined 
to determine if the presence of any particular mutations 
made any cell line more or less responsive to treatment 
with 20-223. We did not find any obvious correlation 
between IC
50
 values and the mutational profile. Based 
RQWKHVHILQGLQJVZHFRQFOXGHWKDWLVDVXEȝ0
inhibitor of CRC cell growth. Specifically, these data show 
that 20-223 is ~2.2 fold and ~31.7 fold more potent than 
AT7519 and Roscovitine, respectively. Therefore, 20-223 
is comparable or marginally better than the CDK inhibitors 
advanced to the clinics.
Reduced CRC cell growth and tumor growth 
induced by 20-223 is probably not due to the 
induction of apoptosis
To determine if induction of apoptosis was 
responsible for potent CRC cell growth inhibition, we 
examined the effect of 20-223 on Poly(ADP-ribose)
polymerase (PARP) cleavage. PARP cleavage is one of the 
hallmarks of cell death and is widely used as a read-out 
of apoptosis in cancer research. To determine the effect 
of 20-223 on cell death, we evaluated the panel of CRC 
cells treated with 20-223 for PARP cleavage. CRC cell 
lines treated with 20-223 for 24 hours all exhibited PARP 
cleavage (Supplementary Figure 5A). Next, we performed 
a dose-response and a time course study in GEO cells and 
IRXQGWKDWȝ0FRQFHQWUDWLRQVRIDQGORQJH[SRVXUH
were required to induce apoptosis (Supplementary Figure 
5B and 5C). This suggests that the reduced tumor growth 
observed in the mouse model is not due to induction of 
apoptosis.
Reduced CRC cell growth and tumor growth in 
mice is probably due to the induction of cell cycle 
arrest by 20-223
The CDK family has been extensively studied 
for its regulation of all phases of the cell cycle. This 
kinase family is essential for normal cells to proliferate 
and divide. CDK2 has been shown numerous times to 
be required for progression from G1 and S phase of the 
cell cycle [40]. The role of CDK5 in cell cycle is less 
understood however, recent reports suggest it regulates the 
cell cycle through mitotic control and dysregulation of cell 
cycle inhibitors, p21CIP1 and p27 [41–43]. Having shown 
that 20-223 effectively targets CDK2 and CDK5 and also 
decreases cell growth, we sought out to understand how it 
may alter cell cycle progression. GEO and HCT116 cells 
were treated with either DMSO, AT7519 or 20-223 for 
24 and 48 hours and then analyzed for DNA content by 
flow cytometry. The results from the above experiment 
are summarized in Figure 6A. 20-223 and AT7519 both 
effectively arrested the CRC cells in either the G2 or S 
phase of the cell cycle. GEO cells treated with either 
20-223 or AT7519 arrested in G2 phase of the cell 
cycle (Figure 6B). This is consistent with the previous 
findings that CDK2 regulates the G2/M checkpoint in 
the absence of functional p53 [44]. Profiling the GEO 
cell line indicates that GEO cells carry a p53 mutation, 
therefore the G2/M arrest seen in GEO cells may be due 
to CDK2 inhibition. Alternatively, the G2 arrest could also 
be attributed to CDK1 inhibition as it was the third CDK 
inhibited in our profiling. HCT116 cells treated with either 
20-223 or AT7519 resulted in S-phase arrest at the 24 and 
48 hour time point. Figure 6B shows representative traces 
from the cell cycle analyses. The data clearly shows that 
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Figure 4: 20-223 disrupts migration of CRC cells. (A) Wound gap images taken during the 24 hour incubation of HCT116 cells 
ZLWK'062RUȝ0DQGKRXULPDJHVZHUHIXUWKHUHYDOXDWHGE\RXWOLQLQJWKHZRXQGDUHDUHGOLQHVDQG]RRPLQJLQRQWKH
wound boundaries (yellow box). (B)4XDQWLILFDWLRQRIZRXQGFORVXUHDIWHUWUHDWPHQWRI+&7FHOOVZLWK'062RIȝ0(C)
:HVWHUQEORWDQDO\VHVDWDQGKRXUVDIWHUVWLPXODWLRQZLWK(*)DQGWUHDWPHQWZLWKHLWKHU'062RUȝ0
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20-223 mimics the effects observed with AT7519. This 
data suggests that the observed CRC cell growth inhibition 
and the tumor growth in mice induced by 20-223 were due 
to cell cycle arrest.
DISCUSSION
There is a need for targeted agents with defined 
mechanism of action for CRC therapy. Recent studies 
have validated CDK5 as a tumor promoter and designated 
Figure 5: 20-223 potently inhibits cell growth in a panel of CRC cell lines. (A) IC
50
 values from growth inhibition studies after 
CRC cells were treated with 20-223, AT7519 or Roscovitine for 72 hours. (B) Average IC
50
 values across all seven CRC cell lines after 
treatment with 20-223, AT7519, or Roscovitine (P < 0.001). (C) Panel containing the seven CRC cell lines used in this study and mutational 
status of important regulatory genes.
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it as a therapeutic target for CRC therapy. In the present 
study, we evaluated 20-223 (CP668863), a previously 
identified CDK5 inhibitor, for its potential as an anti-CRC 
agent. In a proof of concept study, we used an established 
CRC xenograft model to show that 20-223 effectively 
slowed tumor progression. Tumors in mice treated with 
20-223 had reduced tumor volumes and tumor weights 
compared to vehicle-treated mice. Moreover, we observed 
lower levels of phosphorylated FAK, a well-characterized 
target of CDK5, in 20-223 treated tumors as compared to 
Figure 6: 20-223 treatment in CRC cells results in cell cycle arrest in vitro. (A) % of cells in each phase of the cell cycle 
after treatment with DMSO, AT7519, or 20-223 for 24 (top) and 48 (bottom) hours in GEO (left) and HCT116 (right) cells. (B) Traces 
representative of cell cycle analysis in GEO cells after treatment with DMSO, AT7519, or 20-223 after 24 (left) or 48 (right) hours.
Oncotarget5227www.impactjournals.com/oncotarget
vehicle-treated tumors. These results are consistent with 
the studies reported with the neurodegenerative model 
[24].
Having successfully shown that 20-223 slows tumor 
progression in vivo, we followed up with characterization 
of the mechanistic basis for the observed anti-CRC effects 
in cell-free and cell-bases studies. For these studies, 
we used AT7519 and Roscovitine, both CDK inhibitors 
previously explored as anti-cancer CDK inhibitors 
in clinical trials. AT7519 and 20-223 share the same 
core structure, which makes it an optimal compound to 
benchmark the potency of 20-223.
We performed a series of studies to gain insight 
into the mechanism associated with the anti-tumorigenic 
properties elicited by 20-223. The aminopyrazole core 
found in CDK inhibitors has proven successful due to 
the flat heterocyclic core and a series of hydrogen bond 
donors and acceptors. The positioning of nitrogen atoms 
in the aminopyrazole core enables them to compete with 
ATP. A hydrogen bond donor acceptor donor triad within 
the aminopyrazole core targets the hinge region residues 
of the kinase and blocks the binding of ATP [45]. Docking 
studies suggested that aminopyrazole analogs 20-223 and 
AT7519 interact with Glu81 and Cys83 within the hinge 
region of CDK5. Profiling 20-223 against a panel of CDKs 
revealed that it most potently inhibits CDK2 and CDK5 
over other CDKs. Importantly, 20-223 is more potent than 
the clinically used 4-aminopyrazole analog AT7519 in 
cell-free kinase assays.
Cell-based studies corroborated cell-free kinase 
assays as 20-223 effectively disrupted the kinase activity 
of CDK2 and CDK5 in CRC cells. In two of the three cell 
lines profiles 20-223 was selective for CDK5 over CDK2. 
The observed differential sensitivity/selectivity associated 
with 20-223 in three different CRC cell lines suggests that 
the functional misregulation of CDKs is probably not the 
same across the cell lines. The cell free and cell-based 
IC
50
 values were approximately two-orders of magnitude 
apart. This loss of potency when going from a cell free to 
cell-based activity assay is commonly observed in drug 
discovery programs. For example, Palbociclib the recently 
approved CDK4/6 inhibitor has single digit nM potency 
LQFHOOIUHHDVVD\VDQGKDVDVLQJOHGLJLWȝ0SRWHQF\LQ
cell based assays [46]. One possible explanation for this 
observed difference is the emerging view that kinases are 
part of larger protein complexes and evaluating selectivity 
in cell-free conditions does not always reflect the effects 
observed in the cellular context [47].
Since 20-223 showed ~8-fold selectivity for CDK5 
over CDK2 in HCT116 cells we evaluated its efficacy 
in inhibiting migration of HCT116 cells in a wound-
healing scratch assay. 20-223 treated HCT116 cells 
showed reduced cell migration when compared to vehicle 
treated HCT116 cells. This is consistent with reported 
literature that shows that CDK5 plays an important role 
in regulating the migration of cells by phosphorylation of 
Ser732 on FAK [27]. Studies with a CDK2 inhibitor also 
showed it blocked EMT and subsequent cell migration, 
however in that study the effect of the inhibitor on CDK5 
was not determined [30].
As CDK2/5 have been known to drive proliferation 
of cancer cells, we investigated the effect of 20-223 on cell 
growth in a larger panel of CRC cell lines. Among these 
CRC cell lines, 20-223 not only proved to be a nanomolar 
inhibitor of cell growth across the panel, but it was also 
more potent when compared to AT7519 and Roscovitine. 
These results suggest that 20-223 is comparable or in 
some cases more potent than the benchmarked clinical 
aminopyrazole analog AT7519.
Broadly the cause of CRC cell growth inhibition or 
tumor growth inhibition could be either due to induction 
of apoptosis or due cell growth arrest. A dose and time 
dependent study with 20-223 revealed that CRC cells 
UHTXLUHGȝ0FRQFHQWUDWLRQVWRLQGXFH3$53FOHDYDJHD
hallmark for the induction of apoptosis. However at high 
Q0WRORZȝ0FRQFHQWUDWLRQVRI$7RUZH
observed cell cycle arrest. Together our data shows that 
20-223 phenocopies the cell cycle effects of AT7519 in 
CRC cell lines. The observed CRC growth inhibition can 
be largely attributed to inhibition of proliferation and to a 
lesser extent on the induction of apoptosis.
In summary, our study argues for the continued 
preclinical development of 20-223 for CRC therapy. 
Collectively, our results reveal that 20-223 exhibits anti-
cancer properties in a CRC mouse model. Mechanism 
studies indicate that it inhibits CDK2/5 both in vitro and 
in CRC cell lines. Migration of CRC cells was inhibited 
by 20-223, which targeted CDK5 and as a consequence 
inhibited Ser732 phosphorylation a key event in the 
migration of cells. 20-223 inhibits proliferation of CRC 
cell lines by inducing cell cycle arrest. A recent review 
article outlined in detail the contributions of CDK5 to 
many types of cancer, supporting its potential as a novel 
target for cancer therapy across many tumor types [48]. 
While we demonstrated 20-223 is not selective for CDK5, 
it does indeed inhibit CDK5 in vitro and in vivo. 20-223 
had comparable or in several assays better potency than 
the clinically used aminopyrazole CDK inhibitor AT7519, 
which is a good benchmark for advancing a compound 
through development. In order to explore this core for 
improved selectivity, structure activity relationship studies 
are currently underway in our lab and will be reported in 
due course.
MATERIALS AND METHODS
Chemical inhibitors
20-223 was originally designed and synthesized 
by Pfizer (CP668863) and resynthesized in our 
laboratory (20-223) (Supplementary Figure 6). Chemical 
structure was confirmed using proton and carbon NMR 
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(Supplementary Figure 7) and HRMS (Supplementary 
Figure 8A). The purity of the compound was analyzed 
by analytical HPLC (Supplementary Figure 8B). AT7519 
(SelleckChem S1524) and Roscovitine (Apex BioTech 
#A1723) were used in head-to-head comparison studies 
with 20-223. All three inhibitors were dissolved in 100% 
DMSO to a final stock concentration of 10mM.
CRC cell lines and reagents
Cell lines used in this study are colorectal cancer 
(CRC) cell lines. FET, CBS, and GEO cells were cultured 
in serum free medium (McCoy’s 5A medium with sodium 
bicarbonate, L-serine, asparagine, sodium pyruvate, 
0(0 YLWDPLQV JURZWK IDFWRUV ȝJP/ WUDQVIHUULQ
ȝJP/LQVXOLQDQGQJP/(*)DQG[3HQLFLOOLQ
Streptomycin. SW620, DLD1, and HT29 cells were 
cultured in DMEM high glucose medium (HyClone 
#SH30022.01) supplemented with 10% FBS (Gibco 
by Life Technologies #26140-079) and 1x Penicillin-
Streptomycin (HyClone # SV30010). HCT116 cells were 
cultured in RPMI-1640 Medium (HyClone #SH30027.01) 
supplemented with 10% FBS and 1x Penicillin-
Streptomycin. All CRC cell lines were cultured in 5% 
CO
2
 at 37°C. Cell lines were validated by STR profiling at 
the University of Nebraska Medical Center Human DNA 
Identification Laboratory (Supplementary Figure 9A). 
Cell lines exceeding an 80% match with the online ATCC 
database were considered valid [49, 50].
Human colon epithelial cell line
Immortalized non-transformed human colonic 
epithelial cell lines (HCEC) were a gift from J. Shay 
(UT Southwestern)[51]. HCECs were grown in medium 
composed of 4 parts DMEM to 1 part media 199 (Sigma-
Aldrich) with 2% cosmic calf serum (GE Healthcare), 25 
QJP/(*)ȝJP/K\GURFRUWLVRQHȝJP/LQVXOLQ
ȝJP/WUDQVIHUULQQ0VRGLXPVHOHQLWHDQGȝJ
mL gentamycin sulfate. HCECs were grown in a hypoxia 
chamber with 2% O
2
 and 5% CO
2
 at 37°C.
Xenograft studies
All animal studies were carried out following 
approval of the Institutional Animal Care and Use 
Committee. This xenograft study has been used previously 
in our lab [27]. Briefly, GEO-GFP cells (7x106) were 
subcutaneously injected into the flank of athymic nude 
mice. Xenograft tumors were allowed to grow until 
reaching a volume of 100-200mm3 at which point they 
were separated into two treatment groups: DMSO 
vehicle control or 8mg/kg 20-223. Each group contained 
7 animals (n=7). Drug or vehicle injections were given 
subcutaneously daily for the first week and every other 
day for two more weeks for a total of 14 injections. 
Throughout the study, animal weight and tumor volume 
were measured. Tumor volume was measured with 
calipers and calculated using the l2îKîʌHTXDWLRQ
The study was concluded when control tumors reached 
maximum size according to facility guidelines. Mice were 
euthanized and then full body and excised tumor images 
were taken using Near-IR enhanced Macro Imaging 
System Plus Cooled with the LT-99D2 with the Dual Tool 
excitation upgrade. Tumor samples were preserved in 
liquid nitrogen prior to western blot analyses (see below 
for Western Blot protocol).
The cancer genome atlas (TCGA) analyses
TCGA provisional data was retrieved from 
cBioPortal on January 19, 2017. CRC sample type and 
mRNA expression (RNA-seq) was downloaded from 
UCSC Xena (https://genome-cancer.soe.ucsc.edu/proj/
site/xena/heatmap/). All provisional cancer datasets 
were analyzed for CDK5 mutation. The genomic profile 
of CDK5 was further analyzed in the CRC (Colorectal 
Adenocarcinoma - TCGA Provisional) dataset for putative 
somatic copy-number alterations from GISTIC, using 
Onco Query Language (OQL), and mRNA expression 
(RNA-seq). GISTIC predicts copy number alterations 
according to sample specific thresholds generated 
by comparing chromosomal segments with median 
chromosomal arm copy numbers. All parameters were set 
at default.
Cell-free system analyses
Kinase profiling with 20-223 was carried out with 
a panel of CDKs (CDK1, CDK2, CDK4, CDK5, CDK6, 
&'.DQG&'.DWDVLQJOHGRVHȝ0ZLWKȝ0
ATP in duplicates. The enzymatic activity was determined 
for each of the CDKs and follow-up dose response studies 
were carried out with CDK2 and CDK5. A 10-point dose 
UHVSRQVH VWDUWLQJ DW  ȝ0 RI  RU$7 ZLWK
3-fold dilution was carried out. IC
50
 values were generated 
through fitting the dose response curves.
Western blot analyses
Cells were lysed using a buffer containing 
50mM Tris, 100mM NaCl, 1% NP-40, 2mM EDTA, 
20%SDS combined with 20xPPI (Na
3
VO
4
, NAF, 
ȕJO\FHURSKRVSKDWHDQGPPRO/306)6DPSOHVZHUH
kept on ice and vortexed prior to centrifugation at 4°C. 
Supernatant was collected and protein was quantified 
XVLQJ %&$ 3URWHLQ $VVD\ 3LHUFH   ȝJ RI
protein were run on 4-15% gradient gels (BioRad) in 
1x TRIS-Glycine SDS (Research Products International 
Corporation #T32080) at 120V for ~90 minutes and 
separated by SDS-PAGE electrophoresis prior to being 
transferred to a PVDF membrane using a Semi-dry 
transfer (ThermoScienctific, #35035) at 18V for 35 
minutes. The membrane was blocked in 5% milk in 1X 
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Tris Buffered Saline with 0.1%Tween (1xTBST) for 1 
hour at room temperature while gently rocking. Primary 
antibodies (Supplementary Figure 9B) were incubated 
in 5% milk in 1x TBST and rocked overnight at 4°C. 
Appropriate HRP-conjugated secondary antibodies were 
incubated in 5% milk in 1xTBST and rocked for 1 hour at 
room temperature. Protein expression was detected using 
ECL Prime (GE Healthcare #RPN2236). Kinase activity 
was measured by changes in substrate phosphorylation. 
Quantification of phosphorylation levels representative 
of the western blots shown were generated using ImageJ. 
Blots were performed in triplicate (n=3).
Wound healing migration
HCT116 cells were plated at 1.25x106 cells in 2mL 
medium in a 6-well plate and allowed to adhere overnight 
and reach 90% confluency. Cells were scratched using a 
VWHULOHȝ/SLSHWWH WLSGRZQWKHPLGGOHRI WKHZHOO WR
create a “wound”. Scratched cells were washed gently with 
PBS before being stimulated with a final concentration 
of 100ng/mL of EGF (Invitrogen # PHG0311L) and 
LPPHGLDWHO\WUHDWHGZLWKHLWKHUȝ0RU'062
control. Directly after the start of treatment, cells were 
taken to the live cell imaging facility where they were 
imaged every 15 minutes over a 36 hour time course (only 
the first 24 hours were considered for migration purposes). 
Migration assays were performed in triplicate (n=3).
Cell viability
CRC cells were plated at 4000 cells/well in a 96 
well plate. Cells were treated with 20-223, AT7519 or 
5RVFRYLWLQHDWIROGGLOXWLRQVVWDUWLQJDWȝ0
DQG$7RUȝ05RVFRYLWLQHDQGLQFXEDWHGDW
37°C for 72 hours. The ability of these compounds to 
inhibit cell growth was assessed using the dye PrestoBlue. 
Following a 15 minute incubation with PrestoBlue 
reagent (Invitrogen #A13262), fluorescence was 
measured at 560nM excitation and 590nM emission using 
SpectraMax M5e. Growth Inhibition was calculated using 
100-[100*(Sample – T0)/(T100-T0)] equation, where T0 
is the control reading immediately following treatment 
and T100 is the control reading at the end of a 72 hour 
incubation. Each assay was performed in triplicate (n=3).
DNA-cell cycle analyses
CRC cells were plated at 1x106 cells in a 10cm plate 
and allowed to adhere overnight. Cells were starved for 24 
hours prior to treatments at 2x the growth inhibition IC
50
 
values with 20-223, AT7519 or DMSO and were incubated 
for 24 and 48 hours prior to cell cycle analyses. 1x106 cells 
were collected and pelleted by centrifugation at 2000 rpm 
for 1 minute at 4°C. Supernatant was decanted and pellets 
were resuspended in 1mL of 70% Ethanol and incubated 
at 4°C for 1 hour. Samples were centrifuged at 2000 rpm 
for 1 minute at 4°C and ethanol was removed. Pellets were 
washed 1x with 1mL of 1xPBS then centrifuged. PBS was 
removed and samples were resuspended in 1mL of Telford 
5HDJHQW X0('7$ ȝJP/51$VH$ ȝJP/
Propidium Iodide, 0.1% Triton X-100, made in 1xPBS) 
and incubated at 4°C for 1 hr. Cells were analyzed for 
DNA content by flow cytometry. % of cells in the G1, G2, 
and S phases were determined for each treatment. (n=2).
Statistical analyses
Graphs and figures were generated using SigmaPlot 
11.0 and Graphpad Prism statistical software (GraphPad 
Software, Inc). Student’s t-test was used to compare 
differences between means between two groups. One-
way analyses of variance (ANOVA) with a post-test for 
linear trends was used to compare two or more groups. 
For all analyses, significance was inferred at P < 0.05 and 
P values were two-sided.
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